14:40-15:00

Abstract 4000

A randomized   double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with   capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic   pancreatic cancer (mPC).

Ruxolitinib联合卡培他滨二线治疗转移性胰腺癌的随机、双盲、安慰剂对照、II期临床研究。

袁  瑛(Ying   Yuan)

Abstract 4006^

STORM: A phase III randomized, double-blind,   placebo-controlled trial of adjuvant sorafenib after resection or ablation to   prevent recurrence of hepatocellular carcinoma (HCC).

STORM研究：索拉非尼用于肝细胞性肝癌切除或射频术后辅助治疗的随机、双盲、安慰剂对照、III期临床试验。

15:00-15:15

专家评述

Discussion Topic:   Molecular targeted therapy for pancreatic cancer: reality or just myth?

讨论主题：肝癌和胰腺癌分子靶向治疗：现实还是神话？

Margaret A. Tempero

翻译：王  峰(Feng Wang)

15:15-15:20

讨论(Q &   A)

秦叔逵(Shu-Kui Qin)

王理伟(Li-Wei Wang)

Margaret A. Tempero